Over the past 3 months, 4 analysts have published their opinion on TransMedics Group (NASDAQ:TMDX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
TransMedics Group (NASDAQ:TMDX) reported quarterly losses of $(0.38) per share which met the analyst consensus estimate. This is a 31.03 percent decrease over losses of $(0.29) per share from the same period last year.
TransMedics Group (NASDAQ:TMDX) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement.
Analysts estimate that TransMedics Group will report an earnings per share (EPS) of $-0.38.